A Phase 2 interventional study of SBRT and Radiosurgery in Spine Metastasis, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-24.
Sponsored by Chinese University of Hong Kong · Phase 2, Interventional, and Treatment
Demonstrate the technical feasibility of treating spine metastases with image-guided radiosurgery/SBRT
3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.
This study's enrollment of 1 is below the median of 54 across 2,767 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Radiation: SBRT
Radiation: Radiosurgery
•24 Gy in 3 fractions to cover at least 90% of the defined target volume
16 Gy in 1 fraction to cover at least 90% of the defined target volume
Pain control at 3 months post-treatment
Time frame: 4 years
Determine the time of onset of pain response of the responders at the treated site(s) using radiosurgery/SBRT
Time frame: 4 years
Determine the duration of pain response at the treated site(s) using radiosurgery/SBRT
Time frame: 4 years
Study the adverse events of radiosurgery/SBRT according to the criteria in the CTEP Active Version of the CTCAE
Time frame: 4 years
Evaluate the radiological response of image-guided radiosurgery/SBRT by RECIST MRI
Time frame: 4 years
2-year Tumor Control Rate
Time frame: 4 years
Overall Survival
Time frame: 4 years
Quality of life assessment
Time frame: 4 years
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong